Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

It is well-known for its treatments like EPOGEN, Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst at Piper Sandler, reiterated a Buy rating on the stock, with a price ...

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Ratings for Amgen (NASDAQ:AMGN) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their ...

Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst at Piper Sandler, reiterated a Buy rating on the stock, with a price target of $329. Amgen Inc. (NASDAQ ...

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...